Ajay Samkaria: Prevention of Alloimmunization in Females of Childbearing Age
Ajay Samkaria, Product and Application Manager at Diagast Transfusion Medicine, shared a post on LinkedIn:
“In transfusion medicine, prevention is always better than reaction.
One of the most critical yet often under-emphasized practices is extended phenotyping – especially for Rh (C, c, E, e) and Kell antigens in females.
Why does this matter?
Because alloimmunization doesn’t just affect a single transfusion – it can impact future pregnancies and neonatal outcomes.
A young female patient exposed to mismatched Rh or Kell antigens today may develop clinically significant antibodies tomorrow.
These antibodies can lead to Hemolytic Disease of the Fetus and Newborn (HDFN), posing serious risks to both mother and baby.
By proactively providing Rh and Kell matched blood for females of childbearing age, we are not just ensuring safe transfusion – we are protecting future lives.
This is not just good practice.
It is responsible transfusion medicine.
Let’s move from compatibility to foresight.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition